Business Wire

MN-ENTRUST-DATACARD

Share
Entrust Datacard Simplifies High-Assurance Authentication With Next Generation Passwordless Workforce Login and Fully Digital Customer Identity Proofing

Entrust Datacard , a leading provider of trusted identity and secure issuance technology solutions, today announced two new high-assurance offerings for the company’s unified authentication management platform: Passwordless Single Sign On (SSO) Authentication to improve workforce security and productivity, and Identity Proofing with fully digital identity verification for accelerated customer acquisition and onboarding.

As digital transformation, cloud deployments and mobile initiatives make communication, data storage and remote workstyles dramatically simpler, employees and customers around the world expect security features to follow suit, without compromising user experiences. The latest Entrust Datacard authentication solutions both increase high-assurance security and simplify user experiences.

Entrust Datacard’s Passwordless SSO Authentication solution turns employee smartphones into biometrics-protected virtual smart cards that allow instant proximity-based login to both workstations and applications. The solution creates a frictionless authentication experience, eliminating passwords and putting an end to the risk of bad actors stealing user credentials and compromising critical information.

Taking passwordless login to an SSO experience removes the friction of individual registrations and logins for each device, allowing employees to work across devices and applications – cloud-based and on-premises. The solution improves workforce productivity by enabling employees to securely conduct their work activities – email signing, file encryption, document signing, and more – from their office or remote location without the need to upgrade their hardware or operating system.

Entrust Datacard’s new Identity Proofing solution lets banks, hospitals, government agencies and other customer and citizen-facing organizations offer customers a simple, seamless onboarding experience, either inside or outside physical locations. With Identity Proofing, customers use their smartphones or a kiosk to capture their images and scan government-issued identity documents – such as a driver’s license, passport or national ID card – for fast, AI-based authentication and verification.

Once authenticated and verified, the user can complete their account application securely. This minimizes abandoned account applications, cuts onboarding time from multiple days to minutes and has the potential to reduce an organization’s onboarding costs from hundreds of dollars per account to single digits. The fully digital Identity Proofing solution supports compliance with regional regulations, such as Know Your Customer (KYC) and Anti-Money Laundering (AML) in the United States, and PSD2 in Europe.

“Digital transformation is driving the demand for authentication that is both incredibly easy and highly secure – features once thought incompatible,” said James LaPalme, VP and GM of Authentication at Entrust Datacard. “By delivering passwordless SSO authentication, enterprises can eliminate passwords and transform the employee experience, while increasing privacy and data security. Similarly, our Identity Proofing solution creates a truly digital customer onboarding experience, streamlining and automating what has until now been a costly, manual and less-secure process behind the scenes.”

To learn more about the Entrust Datacard Passwordless SSO Authentication and Identity Proofing solutions visit RSA Conference booth #S-2139 from February 24-28 at the Moscone Center in San Francisco or head to https://www.entrustdatacard.com/products/categories/authentication .

About Entrust Datacard Corporation

Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure issuance technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates, hardware security modules and secure communications. With more than 2,800 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye